Home
About
Overview
Sharing Data
ORCID
Help
History (1)
Anti-CD73 and anti-OX40 immunotherapy coupled with a novel biocompatible enzyme prodrug system for the treatment of recurrent, metastatic ovarian cancer.
See All Pages
Find People
Find Everything
Login
to edit your profile (add a photo, awards, links to other websites, etc.)
Edit My Profile
My Person List (
0
)
Return to Top
Anti-CD73 and anti-OX40 immunotherapy coupled with a novel biocompatible enzyme prodrug system for the treatment of recurrent, metastatic ovarian cancer.
Anti-CD73 and anti-OX40 immunotherapy coupled with a novel biocompatible enzyme prodrug system for the treatment of recurrent, metastatic ovarian cancer. Cancer Lett. 2018 07 01; 425:174-182.
View in:
PubMed
subject areas
5'-Nucleotidase
5'-Nucleotidase
Animals
Animals
Annexin A5
Annexin A5
Antibodies
Antibodies
Antineoplastic Combined Chemotherapy Protocols
Antineoplastic Combined Chemotherapy Protocols
Cell Line, Tumor
Cell Line, Tumor
Cystathionine gamma-Lyase
Cystathionine gamma-Lyase
Drug Synergism
Drug Synergism
Female
Female
Humans
Humans
Immunotherapy
Immunotherapy
Mice
Mice
Neoplasm Metastasis
Neoplasm Metastasis
Neoplasm Recurrence, Local
Neoplasm Recurrence, Local
Ovarian Neoplasms
Ovarian Neoplasms
OX40 Ligand
OX40 Ligand
Prodrugs
Prodrugs
Recombinant Fusion Proteins
Recombinant Fusion Proteins
T-Lymphocytes, Cytotoxic
T-Lymphocytes, Cytotoxic
Xenograft Model Antitumor Assays
Xenograft Model Antitumor Assays
authors with profiles
Doris M Benbrook
Kathleen Moore
Roger G Harrison